At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
alitretinoin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Oral Alitretinoin Treatment in Patients With Palmo-plantar Pustulosis (PPP) Inadequately Responding to Standard Topical Treatment
In Brief
A Phase 2 clinical trial evaluating alitretinoin and Placebo for Psoriasis. Completed, enrolled 33 participants across 8 sites in 4 countries.
Detailed Summary
The main purpose of this study is to demonstrate the improvement in the skin condition rate of patients receiving alitretinoin compared to patients receiving placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesFrance, Germany, Netherlands, United Kingdom
CollaboratorsBasilea Pharmaceutica
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartApr 2011
Primary CompletionMar 2014
Study CompletionApr 2014
TodayJul 2026
First PostedNov 22, 2010
Enrollment StartApr 26, 2011
Primary CompletionMar 12, 2014
Study CompletionApr 16, 2014
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 15.6 years ago
Interventions
alitretinoindrug
to receive verum (20 patients)
Placebodrug
to receive placebo (10 patients)